Verrata™ Pressure Guide Wire and iFR® (Instant Wave-Free Ratio™) Software Modality will be on display at EuroPCR 2013[1]

  Verrata™ Pressure Guide Wire and iFR® (Instant Wave-Free Ratio™) Software
                Modality will be on display at EuroPCR 2013[1]

  PR Newswire

  SAN DIEGO, May 21, 2013

-- Volcano Highlights Two Products Intended to Expand the Role of Physiology
in the Cath Lab

SAN DIEGO, May 21, 2013 /PRNewswire/ --Volcano Corporation (NASDAQ: VOLC) a
leading developer and manufacturer of precision guided therapy tools designed
to enhance the diagnosis and treatment of coronary and peripheral vascular
disease, today announced that it will demonstrate the Verrata™ Pressure Guide
Wire and the iFR® (Instant wave-Free Ratio™) modality throughout the week
during the EuroPCR 2013 Congress in Paris, France. These two interventional
tools are intended to help physicians guide more procedures and make more
decisions based on actual heart function, rather than relying on the angiogram

"Despite all the questions that surround percutaneous coronary interventions
(PCI) today, there is an exciting evolution taking place in the form of more
precise stenting decisions and guidance with physiology tools like Fractional
Flow Reserve (FFR)," commented Joe Burnett, Executive Vice President and
General Manager of the Functional Management Business Unit at Volcano. "Data
from the DEFER, FAME and FAME II trials have repeatedly provided evidence that
FFR is the best and most evidence-based diagnostic tool available to help
properly diagnose a patient's vessel, or even a specific blockage. In the five
years since FAME, it is increasingly uncommon that a physician makes a
decision based on angiography alone, without some sort of functional
assessment being performed. We believe that FFR is the most proven
vessel-specific assessment available."

"Physiology will continue to evolve," added Burnett. "Even though FFR is
routinely used to decide if a patient needs treatment, daily practice often
reverts back to the basic angiogram to select which lesions get treated and to
confirm the treatment was successful. There is a tremendous amount of
information physiology can provide that we have yet to unlock in daily
practice. The Verrata wire and iFR modality are designed to continue that
evolution to allow physicians to quickly and easily get valuable functional
information throughout a stent procedure."

The Verrata™ Pressure Guide Wire will be Volcano's fifth new pressure guide
wire in the past five years. It embodies a new wire design and workflow
designed to facilitate fast, simple connections and re-connections throughout
a procedure. "The proposed workflow of the new wire is ideal because it would
more closely mimic standard guidewire use in everyday practice," commented
Bruce Samuels, MD of Cedars-Sinai Hospital in Los Angeles, CA. "The biggest
difference between an everyday interventional wire and a pressure wire is the
large, heavy connector that resides on the end. The design of the new Verrata
wire would allow me to very quickly and easily disconnect and reconnect the
wire with no interruption to my workflow. Re-connecting a pressure wire is now
faster than re-connecting the indeflator for a stent delivery system, which
would allow me to steer the Verrata wire just like a standard interventional
wire with no connector, and simply reconnect any time I want to take a
measurement. This is ideal for delivering devices like balloons and stents
over the wire, and then making valuable physiologic measurements after each
step. I can forsee the functional improvement that my therapy will have on the
patient and not be forced to only trust the angiogram."

Our new iFR® software modality was developed in concert with Imperial College
London. Using the same pressure wire and equipment currently used for FFR,
iFR® amplifies the patient's physiologic measurements during resting
conditions before stressing the heart with a commonly used vasodilator drug,
like Adenosine.

"I continue to be amazed at how inaccurate the angiogram can be," commented
Matthias Gotberg, Interventional Cardiologist, Department of Coronary Heart
Disease,Skane University Hospital, Lund, Sweden. "Physiology uncovers very
important functional information that simply disagrees with the angiogram and
should not be ignored. By making this meaningful measurement in seconds,
physicians can get physiologic answers, but in a workflow almost identical to
how they perform angiographic PCI today. In essence, you can repeatedly
double-check the angiogram with actual heart function and add very little time
to your procedure. I have had access to the live software for more than three
months now. Quite simply, today I am making functional measurements with iFR
that before I would have left to angiography alone."

"iFR and FFR look at the same lesion, but from two different viewpoints," said
Justin Davies, MBBS, MRCP, PhD, of Imperial College London. "FFR will always
be an important tool for us in the lab. It creates a 'worst-case-scenario' to
rule out ischemia, and patients with a negative FFR test do very well
clinically with medical therapy alone. At the same time, retrospective iFR
core lab analysis in over 1,500 patients suggests that more than half of our
patients could avoid the need for hyperemic drugs and still benefit from the
proven value of these physiologic assessments. ADVISE II will be the very
first prospective, multi-center independent study using the currently
available Volcano/Imperial iFR algorithm to seek to confirm this hypothesis."

Results from the first 300 ADVISE II patients will be presented at EuroPCR as
part of the Hot Line late-breaking clinical trial session on Thursday, May
23rd at 10:09 AM in Room 351.

Both the Verrata™ Pressure Wire and the iFR® software modality will be
compatible with Volcano's multi-modality imaging systems including the latest
CORE™ Integrated System which will also be on display at EuroPCR 2013. iFR® is
currently active in more than 20 centers around the world. Hospitals in
London, Rotterdam and Johannesburg will be transmitting live iFR® cases
throughout this week at PCR. "These two new tools will make physiology more
accessible and mainstream, and that is a good thing for hospitals and
patients," continued Burnett. "The easier it is for a physician to
double-check the angiogram, the better. Having both iFR and FFR on the same
system, just one click away, only expands the options to do so. This is a very
exciting time for Volcano's physiology program as we are executing our vision
of a frontline interventional wire workflow that can quickly and easily
provide functional information beyond angiography."

About Volcano Corporation Volcano Corporation is revolutionizing the medical
device industry with a broad suite of technologies that make imaging and
therapy simpler, more informative and less invasive. Our products empower
physicians around the world with a new generation of analytical tools that
deliver more meaningful information - using sound and light as the guiding
elements. Founded in cardiovascular care and expanding into other
specialties, Volcano is changing the assumption about what is possible in
improving patient outcomes by combining imaging and therapy together.

Forward-Looking Statements This press release contains forward-looking
statements within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995. Any statements in this release that are not historical facts may
be considered "forward-looking statements," including statements regarding the
evolution of physiology, anticipated new product introductions, including the
Verrata™ Pressure Guide Wire and iFR® software modality, uses and potential
benefits of these new products, and potential new products and workflows.
Forward-looking statements are based on management's current expectations and
are subject to risks and uncertainties which may cause Volcano's results to
differ materially and adversely from the statements contained herein. Some of
the potential risks and uncertainties that could cause actual results to
differ include the pace and extent of market adoption of the company's
products and technologies; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; unexpected regulatory actions or delays or government
regulation generally; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection; competition in general;
government, industry and general public pricing pressures; unexpected
manufacturing issues; growth strategies; timing and achievement of product
development milestones; outcome of ongoing litigation; the impact and benefits
of market development; product introductions; unexpected new data, safety and
technical issues; market conditions; and other risks inherent to medical
device development and commercialization. These and additional risks and
uncertainties are more fully described in Volcano's filings made with the
Securities and Exchange Commission, including our recent quarterly report on
Form 10-Q. Undue reliance should not be placed on forward-looking statements
which speak only as of the date they are made. Volcano undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made, or to
reflect the occurrence of unanticipated events.

[1] Verrata™ Pressure Guide Wire is pending 510(k) and CE mark, and is not
commercially available for sale. Our iFR® software modality is approved in CE
mark countries.

Contact: Edrienne Brandon, Volcano Corporation,,
+1-858-720-4136; Investor contact: Neal Rosen,,
Press spacebar to pause and continue. Press esc to stop.